Ticker
Unknown company
$40 Trillion and Parents' Night Out Plus: ICE chillin', Moderna-Merck melanoma advances, and more... Let's all admit libertarians were right: The national debt just hit $40 trillion for the first time ever, "an ominous milestone for an economy that sits on a shaky fiscal foundation after decades of … [+7351 chars]
Source ↗Moderna and Merck shares soar on mRNA cancer vaccine Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for M… Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial… [+146 chars]
Source ↗Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations Moderna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran, met the main goal of reduc... Moderna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran, met the main goal of reducing melanoma recurrence and also showed a … [+5790 chars]
Source ↗Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials. Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field … [+1934 chars]
Source ↗US stocks: US market rises as yields ease, Moderna lifts healthcare stocks US stock markets enjoyed a boost as easing bond yields and a spike in Moderna shares contributed to a favorable trading environment. Despite the Federal Reserve's minutes highlighting inflation concerns and discussions on rate hikes, investors remained optimi… The main U.S. stock market indexes closed modestly higher on Wednesday, as easing government bond yields boosted risk appetite while a dramatic rally in shares of vaccine-maker Moderna drove gains in… [+3424 chars]
Source ↗Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients. Moderna and Merck said Wednesday their personalized mRNA cancer vaccine met its main goals in a Phase 3 trial targeting melanoma, marking the first time a therapy of its kind has succeeded at that st… [+6827 chars]
Source ↗Moderna Stock Skyrockets Over 100% Shares of Moderna more than doubled Wednesday after the company and Merck announced promising results Shares of Moderna more than doubled Wednesday after the company and Merck announced positive results from a late-stage trial of an experimental cancer vaccine, though the companies have yet to releas… [+2958 chars]
Source ↗Moderna Cancer Trial Success Is a Shot in the Arm for Trump President Donald Trump has a good claim, rhetorically at least, to one of the technologies that his own movement sometimes loves to hate. On Wednesday, Moderna shares soared higher after the company and Merck announced that their personalized mRNA cancer trea… President Donald Trump has a good claim, rhetorically at least, to one of the technologies that his own movement sometimes loves to hate.On Wednesday, Moderna shares soared higher after the company a… [+141 chars]
Source ↗Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t Convinced The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the... The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with … [+4682 chars]
Source ↗Breaking: Moderna’s mRNA Flu Vaccine Gets Unanimous Thumbs-Up Despite Risks, Low Efficacy The FDA’s Vaccines and Related Biological Products Advisory Committee today voted 9-0 to recommend approval of Moderna’s mRNA flu vaccine for the 50-64 and 65-plus age groups. Karl Jablonowski, Ph.D., senior research scientist for Children’s Health Defense, s… The FDAs Vaccines and Related Biological Products Advisory Committee today voted 9-0 to recommend approval of Modernas mRNA flu vaccine for the 50-64 and 65-plus age groups. Karl Jablonowski, Ph.D., … [+11526 chars]
Source ↗Is Merck & Co. (MRK) One of the Best Cheap Stocks to Buy for Beginners? Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc. (NYSE:MRK) announced on June 1... Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc. (NYSE:MRK) announced on June 1 detailed results from a planned five-year… [+2281 chars]
Source ↗No disclosed trades for $MRNA.